Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

58/433 Matches for
“comorbidities”

“comorbidities” Clear all
  1. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 100

    …Patients underwent an objective assessment of COPD comorbidities, including sleep studies. Biological…

    FibroTest NashTest SteatoTest Metabolic

  2. Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.

    Natarajan Y et al. · Dig Dis Sci · 2017 Match 100

    ### Background Medical comorbidities and functional status limitations are determinants of mortality in…

    FibroTest HCV

  3. Guidelines for the diagnosis of uncomplicated cirrhosis.

    Fontaine H et al. · Gastroenterol Clin Biol · 2007 Match 99

    FibroTest Alcohol HBV HCV +2

  4. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.

    Preda CM et al. · Liver Int · 2018 Match 98

    …score 3-Fibromax), 37% with comorbidities, 10.4% with Child Pugh A6…

    FibroTest HCV

  5. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 97

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…

    FibroTest NashTest SteatoTest Metabolic

  6. Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.

    Tran A et al. · Clin Res Hepatol Gastroenterol · 2022 Match 96

    Hepatitis C virus (HCV) infection is a major cause of chronic liver…

    FibroTest HCV

  7. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 95

    In the current era of therapy with direct-acting antiviral (DAAs) drugs…

    FibroTest HCV

  8. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Match 94

    ### Background And Objective Obstructive sleep apnoea (OSA) could be an independent risk…

    NashTest SteatoTest Metabolic

  9. American Association for the Study of the Liver

    Match 94

    FibroTest HCV

  10. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 93

    FibroTest SteatoTest Metabolic

  11. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 92

    **Background/Objectives**: Prior research has identified a significant association between heart disease…

    FibroTest Metabolic

  12. Late presentation of chronic viral hepatitis for medical care: a consensus definition.

    Mauss S et al. · BMC Med · 2017 Match 91

    ### Introduction We present two consensus definitions of advanced and late stage liver…

    FibroTest HBV HCV

  13. La Haute Autorite de Sante (HAS) in France— Diagnosis of uncomplicated cirrhosis (Accessed December 2011)

    Match 90

    FibroTest Alcohol HBV HCV +2

  14. Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.

    Kucharska M et al. · Pol Arch Intern Med · 2017 Match 89

    …factors, HCV genotype, coinfections, and comorbidities. ### Results Cirrhosis or significant fibrosis (METAVIR…

    FibroTest HCV

  15. Implementing non-invasive markers for liver fibrosis in clinical practice.

    Sebastiani G et al. · J Hepatol · 2008 Match 88

    FibroTest HCV

  16. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?

    Castera L et al. · J Hepatol · 2007 Match 88

    FibroTest HCV

  17. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.

    Bauer B et al. · JAMA Dermatol · 2017 Match 87

    ### Importance The long-term implications of hepatotoxic effects in patients with psoriasis…

    FibroTest NashTest

  18. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.

    Poynard T et al. · Ann Intern Med · 2013 Match 86

    FibroTest HCV

  19. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 85

    ### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…

    FibroTest NashTest SteatoTest HIV

  20. Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.

    Munteanu M et al. · Am J Gastroenterol · 2014 Match 84

    FibroTest HBV

  21. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.

    Bourliere M et al. · J Viral Hepat · 2006 Match 83

    …hepatitis C patients without patent comorbidities. The combination of all tests with…

    FibroTest HCV

  22. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 82

    ActiTest FibroTest NashTest-2 Metabolic

  23. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 82

    …prospective design, respect of procedures, comorbidities, and duration between biopsy and serum…

    FibroTest Alcohol HBV HCV +1

  24. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre.

    Moussalli J et al. · Gastroenterol Res Pract · 2010 Match 81

    Barriers to management of HCV in injection drug users are related to…

    ActiTest FibroTest HCV

  25. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 80

    …age, patient comorbidities, and fibrosis or NASH prevalence), which may lead to…

    FibroTest Metabolic

  26. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 79

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  27. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 78

    ### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…

    FibroTest HBV HCV HIV +1

  28. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 77

    ### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…

    FibroTest Metabolic

  29. Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.

    Trnačević E et al. · Med Glas (Zenica) · 2021 Match 76

    Aim To assess concordance of eight frequently used serology-based scoring indices…

    FibroTest HCV

  30. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Match 75

    ### Aim The objective of this study was to evaluate liver fibrosis using…

    FibroTest

  31. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

    Sebastiani G et al. · World J Gastroenterol · 2007 Match 75

    ### Aim To assess the performance of several non-invasive markers and of…

    FibroTest HBV

  32. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

    Steininger K et al. · J Viral Hepat · 2017 Match 74

    Acute hepatitis C virus infection remains a major health concern in human…

    FibroTest HCV HIV

  33. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 73

    ### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…

    FibroTest NashTest SteatoTest Metabolic

  34. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 72

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  35. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Match 71

    ### Importance There is a need for noninvasive tools to monitor hepatotoxicity in…

    FibroTest Other

  36. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

    Thabut D et al. · Am J Gastroenterol · 2006 Match 70

    ### Background Few data are available on chronic hepatitis C (CHC) in elderly…

    FibroTest HCV

  37. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.

    Zarski JP et al. · J Hepatol · 2012 Match 69

    ### Background & Aims Blood tests and transient elastography (Fibroscan™) have been developed as…

    FibroTest HCV

  38. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.

    Naveau S et al. · Eur J Gastroenterol Hepatol · 2014 Match 69

    ### Background And Aims The PGAA index was one of the first composite…

    FibroTest Alcohol

  39. Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.

    Wilson TG et al. · Int J Cardiol · 2018 Match 68

    ### Background Hepatic and renal dysfunction have been observed in survivors of the…

    FibroTest Other

  40. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 67

    Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…

    ActiTest FibroTest Alcohol HBV +2

  41. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 66

    ### Background No blood test has been shown to be effective in the…

    LCR1 LCR2 Alcohol HBV +4

  42. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 65

    ### Background Studies have demonstrated that coronary artery calcification on one hand and…

    ActiTest FibroTest NashTest SteatoTest +1

  43. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Match 64

    ### Background & Aims Noninvasive tests (NITs) of liver fibrosis have been suggested to…

    FibroTest Metabolic

  44. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.

    Dezanet LNC et al. · Liver Int · 2021 Match 63

    ### Background & Aims Data on liver fibrosis evolution and its involvement in liver…

    FibroTest HBV HIV

  45. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.

    Boyd A et al. · J Int AIDS Soc · 2017 Match 63

    ### Introduction Long-term tenofovir disoproxil fumarate (TDF) use has been associated with…

    FibroTest HBV HIV

  46. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 62

    Liver biopsy, due to its limitations and risks, is an imperfect gold…

    ActiTest FibroTest SteatoTest Alcohol +5

  47. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 61

    FibroTest HBV

  48. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.

    Khalaf N et al. · Clin Gastroenterol Hepatol · 2015 Match 60

    ### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…

    FibroTest HCV

  49. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 59

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  50. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Match 58

    ### Background African Americans have lower reported likelihood of hepatitis C virus-related…

    ActiTest FibroTest HCV

  51. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

    Afdhal NH et al. · J Viral Hepat · 2013 Match 57

    Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…

    ActiTest FibroTest HCV

  52. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 57

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  53. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 56

    ActiTest FibroTest HCV

  54. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 55

    ActiTest FibroTest HBV

  55. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 54

    ActiTest FibroTest HBV

  56. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    Match 53

    FibroTest HCV

  57. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 52

    ### Background Excessive alcohol consumption may lead to the development of alcohol-related…

    FibroTest Alcohol

  58. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.